|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 9/00 | (2006.01) |
| A61K 31/216 | (2006.01) | ||
| A61K 9/20 | (2006.01) | ||
| A61K 31/41 | (2006.01) |
| (11) | Number of the document | 2295035 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10173506.6 |
| Date of filing the European patent application | 2008-11-04 | |
| (97) | Date of publication of the European application | 2011-03-16 |
| (45) | Date of publication and mention of the grant of the patent | 2016-05-18 |
| (46) | Date of publication of the claims translation | 2016-08-25 |
| (30) | Number | Date | Country code |
| 985668 P | 2007-11-06 | US |
| (72) |
Al-Fayoumi, Suliman, US
Hu, Jiahui, US
Kumaraperumal, Natrajan, US
Royce, Alan Edward, US
Ruegger, Colleen, US
Zannou, Erika Aina, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Dvigubo poveikio farmacinės kompozicijos angiotenzino receptorių antagonisto / blokatoriaus (arb) ir neutralios endopeptidazės (nep) inhibitoriaus superstruktūrų pagrindu |
| Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor |
| Payment date | Validity (years) | Amount | |
| 2016-10-18 | 9 | 208.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2017-08-06 |